Treatment approaches aim to restore or mimic p53's function in cells where it has gone awry. For example, scientists have developed small molecules that can bind to mutant p53 and stabilize its ...

Nevertheless, how p53 modulates TIME is still elusive ... serve as a potential immunotherapy for cancer patients with TP53 ...

When analyzing the p53 sequence, she noticed that it looked similar to many other known transcription factors. “At the time, my first hypothesis was it was a transcriptional repressor,” Lozano ...

Yin et al. used a p53-inducible system comprising EB-1 cells derived from a human colon cancer with mutant p53. They observed that PAC1 transcription was induced in these cells in response to serum ...

PMV Pharmaceuticals, Inc.’s PMVP share price has surged by 7.83%, which has investors questioning if this is right time to ...

Advancing the compound into a phase 2/3 trial is a landmark moment for p53 as a drug target, with prior efforts to develop drugs that target mutant p53 held back by difficulties in finding a ...

Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.

It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman ...

anti-cancer drugs for the reactivation of mutant p53 proteins. If Actavalon is successful, it would have the most significant impact on the fight against cancer to date. Since his 2006 retirement from ...